Dermata Therapeutics, Inc. (DRMA)

NASDAQ: DRMA · IEX Real-Time Price · USD
0.257
-0.384 (-59.88%)
At close: Dec 5, 2022 4:00 PM
0.250
-0.007 (-2.76%)
After-hours: Dec 5, 2022 5:09 PM EST
-59.88%
Market Cap 7.75M
Revenue (ttm) n/a
Net Income (ttm) -10.49M
Shares Out 12.28M
EPS (ttm) -1.85
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 6,251,203
Open 0.263
Previous Close 0.641
Day's Range 0.224 - 0.288
52-Week Range 0.224 - 2.732
Beta n/a
Analysts Buy
Price Target 7.65 (+2,876.7%)
Earnings Date Nov 21, 2022

About DRMA

Dermata Therapeutics, Inc., a clinical-stage biotechnology company, focuses on identifying, developing, and commercializing pharmaceutical product candidates for the treatment of medical and aesthetic skin conditions. The company's lead product candidate is DMT310, which has completed Phase IIb clinical trial for treatment of moderate-to-severe acne; and Phase Ib proof of concept (POC) trial for Mild-to-Moderate Psoriasis, as well as is in a Phase 2 clinical trial for treatment of moderate-to-severe rosacea. It is also developing DMT410 that ha... [Read more]

Industry Biotechnology
IPO Date Aug 13, 2021
Employees 8
Stock Exchange NASDAQ
Ticker Symbol DRMA
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 8 analysts, the average rating for DRMA stock is "Buy." The 12-month stock price forecast is 7.65, which is an increase of 2,876.65% from the latest price.

Price Target
$7.65
(2,876.65% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Dermata Announces Topline Results from DMT310 Phase 2 Clinical Trial for the Treatment of Moderate-to-Severe Rosacea

- Data supportive of DMT310 as a treatment for inflammatory skin diseases, but rosacea study did not meet primary endpoints - - DMT310 produced no serious adverse events related to treatment - - Dermata...

9 hours ago - Accesswire

Dermata Therapeutics Provides Corporate Update and Reports Third Quarter 2022 Financial Results

- DMT310 Phase 2 topline results in moderate-to-severe rosacea anticipated in December 2022 - - Initiation of DMT310 Phase 3 for moderate-to-severe acne expected in 1H 2023 - SAN DIEGO, CA / ACCESSWIRE ...

3 weeks ago - Accesswire

Dermata to Present at the H.C. Wainwright 24th Annual Global Investment Conference

SAN DIEGO, CA / ACCESSWIRE / September 6, 2022 / Dermata Therapeutics, Inc. (Nasdaq:DRMA) ("Dermata" or the "Company"), a clinical-stage biotechnology company focusing on the treatment of medical and ae...

2 months ago - Accesswire

Dermata to Participate in the Gilmartin Group Emerging Growth Company Showcase

SAN DIEGO, CA / ACCESSWIRE / August 24, 2022 / Dermata Therapeutics, Inc. (Nasdaq:DRMA) ("Dermata," or the "Company"), a clinical-stage biotechnology company focusing on the treatment of medical and aes...

3 months ago - Accesswire

Dermata Therapeutics Provides Corporate Update and Reports Second Quarter 2022 Financial Results

Dermata completes a $5.0 million private placement financing in April 2022 DMT310 Phase 2 rosacea trial topline results expected in the second half of 2022 SAN DIEGO, CA / ACCESSWIRE / August 15, 2022 /...

3 months ago - Accesswire

Dermata Announces Final Patient Enrolled in a Phase 2 Trial of DMT310 for the Once-Weekly Treatment of Moderate-to-Se...

- Topline results expected in the second half of 2022 - - Rosacea affects about 16 million patients in the U.S. - SAN DIEGO, CA / ACCESSWIRE / June 13, 2022 / Dermata Therapeutics, Inc. ("Dermata," or t...

5 months ago - Accesswire

Dermata to Present at the H.C. Wainwright Global Investment Conference

SAN DIEGO, CA / ACCESSWIRE / May 23, 2022 / Dermata Therapeutics, Inc. (NASDAQ:DRMA) ("Dermata" or the "Company"), a clinical-stage biotechnology company focusing on the treatment of medical and aesthet...

6 months ago - Accesswire

Dermata Therapeutics Provides Corporate Update and Reports First Quarter 2022 Financial Results

Dermata completes a $5.0 million private placement financing DMT310 Phase 2 rosacea trial topline results expected in H2 2022 SAN DIEGO, CA / ACCESSWIRE / May 16, 2022 / Dermata Therapeutics, Inc. (NASD...

6 months ago - Accesswire

Dermata Therapeutics Announces Closing of $5.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules

SAN DIEGO, CA / ACCESSWIRE / April 25, 2022 / Dermata Therapeutics, Inc. ("Dermata," or the "Company") (NASDAQ:DRMA) (NASDAQ:DRMAW), a clinical-stage biotechnology company focusing on the treatment of m...

7 months ago - Accesswire

Dermata Therapeutics Announces $5.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules

SAN DIEGO, CA / ACCESSWIRE / April 21, 2022 / Dermata Therapeutics, Inc. ("Dermata," or the "Company") (NASDAQ:DRMA) and (NASDAQ:DRMAW), a clinical-stage biotechnology company focusing on the treatment ...

7 months ago - Accesswire

Dermata Therapeutics Provides Corporate Update and Reports Full Year 2021 Financial Results

DMT310 Phase 2 rosacea trial is over two-thirds enrolled with topline results expected in H2 2022 DMT310 Phase 2 psoriasis trial to start H1 2022, with topline results expected in H1 2023 DMT310 Phase 3...

8 months ago - Accesswire

Dermata Therapeutics to Participate in the 2022 Maxim Group Virtual Growth Conference

SAN DIEGO, CA / ACCESSWIRE / March 24, 2022 / Dermata Therapeutics, Inc. (NASDAQ:DRMA) ("Dermata" or the "Company"), a clinical-stage biotechnology company focusing on the treatment of medical and aesth...

8 months ago - Accesswire

Dermata Therapeutics Shares Plunge 20% Premarket: What Investors Need To Know

Dermata Therapeutics Inc  DRMA has requested the FDA to waive the requirements to complete a 90-day dermal minipig study and a standard dermal pharmacokinetics study before the End of Phase 2 meeting fo...

9 months ago - Benzinga

Dermata Appoints Life Science Executive Brittany Bradrick to Board of Directors

SAN DIEGO, CA / ACCESSWIRE / January 13, 2022 / Dermata Therapeutics, Inc. (NASDAQ:DRMA) ("Dermata," or the "Company"), a clinical-stage biotechnology company focused on the treatment of medical and aes...

10 months ago - Accesswire

Dermata to Present at the H.C. Wainwright BioConnect Conference

SAN DIEGO, CA / ACCESSWIRE / January 5, 2022 / Dermata Therapeutics, Inc. (NASDAQ:DRMA) ("Dermata" or the "Company"), a clinical-stage biotechnology company focusing on the treatment of medical and aest...

11 months ago - Accesswire

Dermata's Aesthetic Improvement Candidate Fails To Impress - Read Why

Dermata Therapeutics Inc (NASDAQ: DRMA) announced data from its Phase 1b proof of concept study evaluating a single treatment of DMT410 to treat multiple aesthetic skin conditions. DMT410 showed improve...

1 year ago - Benzinga

Dermata Announces Positive Results from DMT410 Phase 1b Proof of Concept Study for Aesthetic Skin Conditions

Observed improvements in pore size, luminosity, brightness, and overall aesthetic appearance Duration of effect lasted approximately 3 months No potential distant spread of toxin observed SAN DIEGO, CA ...

1 year ago - Accesswire

Dermata Announces First Patient Enrolled in its Phase 2 Trial of DMT310 for the Treatment of Moderate-to-Severe Rosacea

Topline results expected in second half of 2022 Rosacea affects about 16 million patients in the U.S. SAN DIEGO, CA / ACCESSWIRE / November 17, 2021 / Dermata Therapeutics, Inc. ("Dermata," or the "Comp...

1 year ago - Accesswire

Dermata Therapeutics, Inc. Reports Third Quarter 2021 Financial Results and Provides Corporate Update

- Announced positive topline results from DMT310 proof of concept (POC) study in mild-to-moderate psoriasis - - Closed upsized $18.0 million initial public offering (IPO) on Nasdaq Capital Market - - To...

1 year ago - Accesswire

Dermata Announces Presentation Details for Its DMT410 Phase 1b Proof of Concept Aesthetic Study at The American Socie...

SAN DIEGO, CA / ACCESSWIRE / November 12, 2021 / Dermata Therapeutics, Inc. ("Dermata," or the "Company") (Nasdaq:DRMA), a clinical-stage biotechnology company focusing on the treatment of medical and a...

1 year ago - Accesswire

Dermata Announces Virtual Investor Event to Present DMT410 Phase 1b Proof of Concept Results in Aesthetic Skin Condit...

SAN DIEGO, CA / ACCESSWIRE / November 11, 2021 / Dermata Therapeutics, Inc. ("Dermata," or the "Company") (NASDAQ:DRMA), a clinical-stage biotechnology company focusing on the treatment of medical and a...

1 year ago - Accesswire

Dermata Stock Jumps On Positive Psoriasis Candidate Data

Dermata Therapeutics Inc (NASDAQ: DRMA) announced topline results from its Phase 1b trial of DMT310 for mild-to-moderate psoriasis.  The percentage of treatment responders in Physician's Global Assessme...

1 year ago - Benzinga

Dermata Announces Positive Results from Phase 1b Clinical Trial of DMT310 for the Treatment of Mild-to-Moderate Psori...

- DMT310 achieved a PGA score of 0 or 1 for the target lesion in 29.6% of patients at Week 8 - - DMT310 demonstrated a total PASI score of 0 or 1 for the target lesion in 25.9% of patients at Week 8 - -...

1 year ago - Accesswire

Dermata Therapeutics, Inc. Reports Second Quarter 2021 Financial Results and Provides Corporate Update

- Completed oversubscribed $18 million Initial Public Offering (IPO) - - Set to announce topline results from its DMT310 Phase 1b proof of concept (POC) study in mild to moderate psoriasis in 4Q 2021 - ...

1 year ago - Accesswire

Why Are Dermata Therapeutics Shares Trading Higher Today?

Brookline has initiated Dermata Therapeutics Inc's (NASDAQ: DRMA) coverage with a Buy rating and $14 price target. Analyst Kumaraguru Raja sees an upside of almost 164%.

1 year ago - Benzinga